Company record
Chiesi USA, Inc.
0 FDA warning letters since 2023 and 3 recalls in the last 12 months.
Get an email the day FDA posts anything new about Chiesi USA, Inc..
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| Sep 9 | Class III | Chiesi USA, Inc. Drug |
Revcovi (elapegademase-lvlr) Injection, 2.4mg/1.5mL (1.6 mg/mL), Single-Dose Vial, Rx Only, For Intramuscular Use Only, Mfd. by Chiesi USA, Inc., Cary, NC 27518, NDC 10122-502-01 Failed Stability Specifications: Out of specification stability result for the protein concentration profile. |
| Jul 22 | Class II | Chiesi USA, Inc. Drug |
CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL), 10 Single Use Vials, Rx Only, Manufactured for: Chiesi USA, Inc., Cary, NC 27518, by Fresenius Kabi, Graz, Austria, NDC 10122-611-10. Lack of Assurance of Sterility |
| Apr 1 | Class II | Chiesi USA, Inc. Drug |
CUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03. Lack of Assurance of Sterility |